openPR Logo
Press release

Global Pulmonary Arterial Hypertension Market Size

Global Pulmonary Arterial Hypertension Market Size

Global Pulmonary Arterial Hypertension Market Size

According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.

Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC on "Global Pulmonary Arterial Hypertension Market- Forecast to 2027'' https://www.globalmarketestimates.com/market-report/pulmonary-arterial-hypertension-market-3787

By Drug Class (Endothelin Receptor Antagonists (ERAs), PDE - 5 Inhibitors, Prostacyclin and Prostacyclin Analogs, and SGC Stimulators), By Type (Branded and Generics), By Route of Administration (Oral, Intravenous/ subcutaneous and Inhalational), By Region (North America, Asia Pacific, Central & South America, Europe, and the Middle East & Africa), End-User Landscape Analysis, Company Market Share Analysis, and Competitor Analysis

Key Market Insights
• As per the type outlook, the generics segment is expected to be the largest segment in the Pulmonary Arterial Hypertension market from 2022 to 2027
• The Asia Pacific region is analyzed to be the fastest-growing segment in the market
• As per the drug class outlook, the prostacyclin and prostacyclin analogs segment is expected to be the largest segment in the Pulmonary Arterial Hypertension market from 2022 to 2027
• North America (the United States, Canada, and Mexico) will have a dominant share in the global pulmonary arterial hypertension market from 2022 to 2027
• United Therapeutics Corporation, Bayer, Gilead Sciences, Inc., Johnson & Johnson, Viatris Inc., GlaxoSmithKline, Sandoz Inc. (Novartis), Lupin Pharmaceuticals, Inc., Sun Pharmaceutical Industries, Inc., and Teva Pharmaceutical Industries Ltd, among others, are the key players in the pulmonary arterial hypertension market.

Drug Class Outlook (Revenue, USD Billion, 2022-2027)
• Endothelin Receptor Antagonists (ERAs)
• PDE - 5 Inhibitors
• Prostacyclin and Prostacyclin Analogs
• SGC Stimulators

Type Outlook (Revenue, USD Billion, 2022-2027)
• Branded
• Generics

Route of Administration Outlook (Revenue, USD Billion, 2022-2027)
• Oral
• Intravenous/ subcutaneous
• Inhalational

Regional Outlook (Revenue, USD Billion, 2022-2027)
North America
• The U.S.
• Canada
• Mexico
Europe
• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe
Asia Pacific
• China
• India
• Japan
• South Korea
• Australia
• Rest of APAC
Central & South America
• Brazil
• Argentina
• Rest of CSA
Middle East & Africa
• Saudi Arabia
• UAE
• Rest of MEA

Contact: Yash Jain
Email address: yash.jain@globalmarketestimates.com
Phone Number: +1 6026667238

B-502, Kemp Plaza, Mindspace, Malad West, Mumbai: 400 064, India

Global Market Estimates is an India based market research and consulting company. The company provides syndicated research reports, customised research reports and consulting services to their clients and helps them achieve their business goals on a commercial level. Global Market Estimates database is used by the world's well known and prolific academic institutions and Fortune 500 companies to understand the global and regional business environment to excel in their business goals.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Pulmonary Arterial Hypertension Market Size here

News-ID: 2619697 • Views: 130

More Releases from Global Market Estimates Research & Consultants

Ship Port Infrastructure Market Size - Forecasts to 2027
According to a new market research report published by Global Market Estimates, the Global Ship Port Infrastructure Market is projected to grow at a CAGR value of 4.5% from 2022 to 2027. The market will be driven during the forecast period by a rise in globalization and international trade activities propelling demand for maritime trade, a rise in government investments and grants in improving port infrastructure, and an expanding global
Global Flexible Hybrid Electronics Market Size - Forecasts to 2027
According to a new market research report published by Global Market Estimates, the Global Flexible Hybrid Electronics Market is projected to grow from USD 0.12 Billion in 2022 to USD 0.27 Billion by 2027 at a CAGR value of 16.5% from 2022 to 2027. Increasing investment by government in research and development and partnerships with tech companies with the intention of promoting the technology to the public, is a prime
Global Maritime Analytics Market Size - Forecasts to 2027
According to a new market research report published by Global Market Estimates, the Global Maritime Analytics Market is projected to grow at a CAGR value of 16.9% from 2022 to 2027. The assistance that companies provide in realigning their business strategies, the growing digitalization of the shipping industry, the rising popularity of marine tourism, and the rising number of ships, including cargo vessels, large ships, oil tankers, cruise liners, and
Global Disposable Medical Device Sensors Market Size - Forecasts to 2027
According to a new market research report published by Global Market Estimates, the Global Disposable Medical Device Sensors Market is projected to grow from USD 0.12 Billion in 2022 to USD 0.27 Billion by 2027 at a CAGR value of 16.5% from 2022 to 2027. Rising need for time-saving medical devices which can be used to measure health-stats at the patient's convenience and rising awareness of remote patient monitoring will

All 5 Releases


More Releases for Pulmonary

Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated
Pulmonary Drugs Market – Boon for Diseased Lungs
Pulmonary Drugs Market – Boon for Diseased Lungs Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated
Global Pulmonary Arterial Hypertension Market to 2024
Global Pulmonary Arterial Hypertension (PAH) market was valued at $5.0bn in 2015 and is forecast to grow at a modest 6.0% CAGR between 2015 and 2024, to result in 2024 global sales of $9.0bn. PAH is broadly split into two classes, primary or secondary. Primary pulmonary hypertension (PPH) refers to pulmonary hypertension occurring without an identifiable cause. Secondary pulmonary arterial hypertension (PAH) occurs in association with some other identifiable medical condition.
Pulmonary Fibrosis Market Professional Survey Report 2017
Global Pulmonary Fibrosis Market: Snapshot Pulmonary fibrosis belongs to the family of interstitial diseases that can lead to damage of the lungs. As the lung tissue becomes stiff and thickened, it interferes with a person’s ability to breathe. The scarring of lung tissues is associated with a multitude of factors. However, in most cases, the cause of the problem can’t be determined. This state is termed as idiopathic pulmonary fibrosis. While the
Pulmonary Drugs 2024 Market Research Report
Global Pulmonary Drugs Market: Snapshot The global pulmonary drugs market has been the key area of focus and the most crucial market for the healthcare industry in the last couple of years. However, the market is expected to witness a significant decline over the forecast period with a -6.3% CAGR from 2016 to 2024. The market is anticipated to fall to US$28,082.1 mn from a valuation of US$48,039.7 mn in
Latest Report: Global Pulmonary Hypertension Market
MarketResearchReports.Biz presents this most up-to-date research on "Pulmonary Hypertension-Pipeline Insights, 2017" DelveInsights, Pulmonary Hypertension-Pipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the Pulmonary Hypertension. The DelveInsightsReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations,